Live Breaking News & Updates on Richard Pencek

Stay updated with breaking news from Richard pencek. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Metacrine to Present Final Results from Phase 1 Trial of MET642, an Optimized FXR Agonist, at ...


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Metacrine to Present Final Results from Phase 1 Trial of MET642, an Optimized FXR Agonist, at .
Metacrine, Inc.March 11, 2021 GMT
SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that final results from the company’s Phase 1 trial of MET642, a farnesoid X receptor (FXR) agonist in development for the treatment of non-alcoholic steatohepatitis (NASH), will be presented as a distinguished abstract at the 2021 NASH-TAG Conference. The conference is taking place March 11-13, 2021 in Park City, Utah and virtually on-line. ....

United States , Park City , Kyoung Jin Lee , Jonathan Lee , Richard Pencek , Steve Kunszabo , Hubertc Chen , Exchange Commission , Metacrine Inc , Non Alcoholic Steatohepatitis , Private Securities Litigation Reform Act , Quarterly Report , Corporate News , Drug Trials , Products And Services , Government Regulations , Clinical Trials , Diagnosis And Treatment , Liver Transplants , Product Testing , Diseases And Conditions , Government And Politics , Medical Research , Liver Disease , Organ Transplants , Globe Newswire ,